

## 해외 바이오의약품 임상 현황 (2020.08.31 ~ 2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

### ○ 미국 104건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04528680	Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma	Glioblastoma Gliosarcoma GBM Glioblastoma Multiforme Glioblastoma, IDH-wildtype Recurrent Glioblastoma	Device: Sonication for opening of blood-brain barrier Drug: Chemotherapy, albumin-bound paclitaxel	Northwestern University CarThera	Phase 1  Phase 2
NCT04517435	ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma	Drug: ME-401 Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone	Deepa Jagadeesh Case Comprehensive Cancer Center	Phase 1  Phase 2
NCT04491877	Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers	Respiratory Syncytial Virus Infection	Biological: RSV vaccine formulation 1 Biological: RSV vaccine formulation 2 Biological: Placebo	Sanofi Pasteur, a Sanofi Company Sanofi	Phase 1  Phase 2
NCT04380545	Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer	Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8 Unresectable Fibrolamellar Carcinoma	Drug: Fluorouracil Biological: Nivolumab Biological: Recombinant Interferon Alpha 2b-like Protein	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1  Phase 2
NCT04285671	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Necitumumab Drug: Osimertinib Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Trastuzumab	Jonsson Comprehensive Cancer Center Eli Lilly and Company Genentech, Inc.	Phase 1  Phase 2
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib Biological: Axicabtagene Ciloleucel	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 1  Phase 2
NCT04201821	Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women	Fecal Incontinence	Biological: fecal microbial transplantation (FMT)	University of Pennsylvania	Phase 1  Phase 2
NCT04121442	Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors	Solid Tumor, Adult	Biological: Isunakinra Biological: PD-(L)1 Inhibitor	Buzzard Pharmaceuticals Baylor Research Institute	Phase 1  Phase 2
NCT04060407	CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)	Metastatic Melanoma Renal Cell Carcinoma Colon Cancer With MSI-H or dMMR	Drug: CD24Fc Drug: Ipilimumab Drug: Nivolumab	Oncolmmune, Inc. Huntsman Cancer Institute	Phase 1  Phase 2
NCT04537910	A Study of LY3819253 (LY-CoV555) in Healthy Participants	Healthy	Drug: LY3819253 Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04535102	POLA+BR for Relapsed or Refractory DLBCL	Diffuse Large B Cell Lymphoma	Drug: Polatuzumab Vedotin	University of Colorado, Denver National Cancer Institute (NCI)	Phase 2
NCT04521764	A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Invasive Breast Carcinoma Metastatic Breast Adenocarcinoma Prognostic Stage IV Breast Cancer AJCC v8 Recurrent Breast Carcinoma	Biological: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein	Mayo Clinic National Cancer Institute (NCI)	Phase 1
NCT04511078	Phase II Pantumumab-IRDye800 in Head & Neck Cancer	Head and Neck Cancer	Drug: Panitumumab-IRDye800	University of Alabama at Birmingham	Phase 2
NCT04510428	OSIG-eye Drops Treatment for Dry Eye Disease	Dry Eye	Drug: Ocular Surface Immune Globulin (OSIG) Drug: Placebo	Sandeep Jain, MD University of Illinois at Chicago	Phase 2
NCT04505254	Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia	Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma	Drug: Acalabrutinib Biological: Obinutuzumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04499053	Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer	Carcinoma, Non-Small Cell Lung	Drug: Durvalumab	Georgetown University AstraZeneca	Phase 2
NCT04495153	GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC	Non Small Cell Lung Cancer	Biological: GMCI	Advantagene, Inc. d.b.a. Candel Therapeutics NYU Langone Health	Phase 2
NCT04493060	Niraparib and Dostarlimab for Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	Metastatic Pancreatic Ductal Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Biological: Dostarlimab Drug: Niraparib	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT04490486	Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19	COVID-19 Acute Respiratory Distress Syndrome Corona Virus Infection	Biological: UCMSCs Other: Placebo	Joshua M Hare University of Miami	Phase 1
NCT04484012	Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma	Drug: Acalabrutinib Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2
NCT04470024	Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without G1TR Agonist, With Anti-PD-1 Immunotherapy in HNSCC	Cancer of the Head and Neck	Drug: INCAGN01876 Drug: INCMGA00012 Biological: DPV-001	Providence Health & Services	Phase 1
NCT04466618	Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes	Healthy Type 2 Diabetes	Biological: Saline Biological: Exendin-9,39 Biological: Saline + Intralipid/Heparin Biological: Exendin-9,39 + Intralipid/Heparin	Adrian Vella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Mayo Clinic	Phase 3
NCT04461015	The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans	Healthy	Drug: 0.4mU Insulin Drug: 0.8mU Insulin	Adrian Vella Mayo Clinic	Phase 3
NCT04459338	A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion	Healthy	Biological: Exendin-9,39 Other: Saline	Adrian Vella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Mayo Clinic	Phase 3
NCT04454489	Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition	Advanced Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma	Drug: Pembrolizumab (immunotherapy) Radiation: Quad-shot palliative radiotherapy	Wake Forest University Health Sciences National Cancer Institute (NCI)	Phase 2
NCT04447768	The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center Genentech, Inc.	Phase 2
NCT04442581	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer	Advanced Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma	Drug: Cabozantinib S-malate Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI)	Phase 2

## 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT04434560	Neoadjuvant Immunotherapy in Brain Metastases	Brain Metastases, Adult	Drug: Nivolumab Drug: Ipilimumab	Sarah Sammons, MD Bristol-Myers Squibb Duke University	Phase 2
NCT04430452	Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition	Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8	Biological: Durvalumab Radiation: Hypofractionated Radiation Therapy Biological: Tremelimumab	Mary Feng, MD AstraZeneca University of California, San Francisco	Phase 2
NCT04420975	Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma	Leiomyosarcoma Myxofibrosarcoma Resectable Dedifferentiated Liposarcoma Resectable Soft Tissue Sarcoma Resectable Undifferentiated Pleomorphic Sarcoma Soft Tissue Fibrosarcoma Spindle Cell Sarcoma Stage I Retroperitoneal Sarcoma American Joint Committee on Cancer (AJCC) v8 Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage IA Retroperitoneal Sarcoma AJCC v8 Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage IB Retroperitoneal Sarcoma AJCC v8 Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage II Retroperitoneal Sarcoma AJCC v8 Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Storiform-Pleomorphic Malignant Fibrous Histiocytoma Synovial Sarcoma Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant	Procedure: Definitive Surgical Resection Drug: Immunotherapeutic Agent Biological: Nivolumab Radiation: Radiation Therapy	Jonsson Comprehensive Cancer Center	Phase 1
NCT04414540	Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients	Head and Neck Squamous Cell Carcinoma	Drug: Metformin Extended Release Oral Tablet Drug: Pembrolizumab	Trisha Wise-Draper American Cancer Society, Inc. University of Cincinnati	Phase 2
NCT04410900	Vaccine Responsiveness After CAR-T Cell Therapy	B-Cell Neoplasm	Biological: Wistar Rabies Virus Strain PM-1503-3M Vaccine Procedure: Biospecimen Collection	Fred Hutchinson Cancer Research Center National Institutes of Health (NIH) National Cancer Institute (NCI)	Phase 1
NCT04406064	Viral Specific T-cells for Treatment of COVID-19	Viral Infection	Biological: Viral Specific T-cells (VSTs)	Children's Hospital Medical Center, Cincinnati Hoxworth Blood Center	Phase 2
NCT04401995	Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab	Melanoma	Drug: CMP-001 Biological: Nivolumab Other: [18F]F-AraG PET/CT	Diwakar Davar Checkmate Pharmaceuticals CellSight Technologies, Inc. University of Pittsburgh	Phase 2
NCT04388709	Interferon Lambda Therapy for COVID-19	SARS-CoV-2	Drug: Peginterferon Lambda-1A	Icahn School of Medicine at Mount Sinai Eiger BioPharmaceuticals	Phase 2
NCT04387227	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma	Drug: Carboplatin Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04383743	Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer	Stage II Bladder Cancer AJCC v8 Stage IIIA Bladder Cancer AJCC v8	Drug: Cisplatin Drug: Doxorubicin Drug: Methotrexate Biological: Pegfilgrastim Biological: Pembrolizumab Procedure: Radical Cystectomy Drug: Vinblastine Sulfate	University of Washington National Cancer Institute (NCI) Merck Sharp & Dohme Corp.	Phase 2
NCT04373265	Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production	Adrenocortical Carcinoma	Drug: Relacorilant Drug: Pembrolizumab	Corcept Therapeutics	Phase 1
NCT04372927	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	Locally Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8	Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Drug: Pemetrexed	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2
NCT04362501	Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)	Chronic Sinusitis	Biological: dupilumab Drug: placebo	Johns Hopkins University	Phase 2
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleucel	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2
NCT04336943	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma	Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2
NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04312113	Angiographic Delivery of AD-MSC for Ulcerative Colitis	Ulcerative Colitis	Drug: Adipose derived, autologous mesenchymal stem cells	Mayo Clinic	Phase 1
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6532	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2
NCT04280471	Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Acute Graft Versus Host Disease Gastrointestinal Tract Acute Graft Versus Host Disease Severe Gastrointestinal Tract Acute Graft Versus Host Disease Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease	Drug: Fecal Microbiota Transplantation Capsule	Jonsson Comprehensive Cancer Center	Phase 1

# 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT04266730	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab	Squamous Cell Lung Cancer Squamous Non-small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck	Biological: PANDA-VAC	UNC Lineberger Comprehensive Cancer Center	Phase 1
NCT04256759	Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus	Pruritus	Drug: Dupilumab 300Mg Solution for Injection	Mayo Clinic Regeneron Pharmaceuticals	Phase 2
NCT04238091	Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata	Alopecia Areata Alopecia Totalis Alopecia Universalis	Drug: Fecal material transfer therapy Procedure: 4mm Punch Biopsy of Scalp Diagnostic Test: Blood draw Procedure: Skin Microbiome sampling Procedure: Hair Microbiome Sampling Drug: Pre-FMT Antibiotic Cocktail Drug: Bowel Prep	Columbia University	Phase 2
NCT04216589	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	HIV Infections Non-Alcoholic Fatty Liver Disease	Drug: Semaglutide	National Institute of Allergy and Infectious Diseases (NIAID) The University of Texas Health Science Center, Houston	Phase 2
NCT04211714	Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure	Telomere Shortening Bone Marrow Failure	Biological: EXG34217	Elixirgen Therapeutics, Inc.	Phase 1
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adult Diffuse Large Cell Lymphoma Anaplastic Large Cell Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Prolymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporine Biological: Filgrastim Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation Drug: Treosulfan	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04153422	IVIg in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS or FGFR-3 Antibodies	Small Fiber Neuropathy Autoimmune Small Fiber Neuropathy Inflammatory Polyneuropathy Immune-Mediated Neuropathy	Drug: Gammagard IVIG Drug: Placebo	Loyola University Takeda	Phase 2
NCT04150692	Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma	Multiple Myeloma	Biological: Daratumumab Procedure: Blood for research assessments Procedure: Bone marrow for research assessments	Washington University School of Medicine Janssen, LP	Phase 2
NCT04140162	Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy	Multiple Myeloma	Drug: Daratumumab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone	University of Michigan Rogel Cancer Center Janssen Scientific Affairs, LLC	Phase 2
NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	Human Papillomavirus Type 16 Cervical Intraepithelial Neoplasia Grade II Cervical Intraepithelial Neoplasia, Grade III	Drug: pNGVL4aCRTE6E7L2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)	Phase 1
NCT0411172	Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies	Pancreatic Ductal Adenocarcinoma Colorectal Adenocarcinoma Gastric Adenocarcinoma Esophageal Adenocarcinoma	Biological: Ad5.F35-hGCC-PADRE	Thomas Jefferson University	Phase 2
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agios Pharmaceuticals, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04044534	Intranasal Insulin for Posttraumatic Stress Disorder	PTSD	Drug: Intranasal insulin Drug: Placebo	VA Connecticut Healthcare System	Phase 2
NCT04038619	Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients	Colitis Diarrhea Malignant Genitourinary System Neoplasm	Procedure: Fecal Microbiota Transplantation Drug: Loperamide	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04024878	NeoVax With Nivolumab in Patients With Ovarian Cancer	Ovarian Cancer	Drug: Nivolumab Biological: NeoVax Procedure: Core Needle Biopsy	Dana-Farber Cancer Institute United States Department of Defense	Phase 1
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Allogeneic Stem Cell Transplant Candidate Acute Myeloid/Lymphoblastic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasm Lymphoproliferative Disorders	Biological: Cellular therapy product	Case Comprehensive Cancer Center	Phase 1
NCT03935594	Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars	Hypertrophic Scar	Biological: PRP Injection Drug: Saline Injection	Vanderbilt University Medical Center	Phase 2
NCT03735277	Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke	Acute Ischemic Stroke	Biological: HPC, Cord Blood	BHI Therapeutic Sciences	Phase 1
NCT03678545	Dupilumab in Eosinophilic Gastritis	Eosinophilic Gastritis Eosinophilic Gastroenteritis	Drug: Dupilumab (blinded) Drug: Placebo (blinded) Drug: Dupilumab (open-label)	Children's Hospital Medical Center, Cincinnati Regeneron Pharmaceuticals	Phase 2
NCT03527108	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC	Non Small Cell Lung Cancer	Drug: Nivolumab Drug: Ramucirumab	Fox Chase Cancer Center Bristol-Myers Squibb Eli Lilly and Company	Phase 2
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Caverosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT03361852	A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma	Follicular Lymphoma	Drug: Rituximab Biological: Neo Vax	Dana-Farber Cancer Institute	Phase 1

## 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT03219450	A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.	Lymphocytic Leukemia	Drug: NeoVax Drug: Cyclophosphamide	Dana-Farber Cancer Institute Oncovir, Inc. BioNTech SE	Phase 1
NCT03068832	Neopeptide-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Pediatric Brain Tumor	Biological: Personalized peptide vaccine Drug: Poly ICLC Procedure: Peripheral blood draw	Washington University School of Medicine	Phase 1
NCT04504279	Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis	Atopic Dermatitis	Biological: FB-401 Biological: Placebo	Forte Biosciences, Inc.	Phase 2
NCT04475523	Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies	Solid Tumor	Drug: CI-8993	Curis, Inc.	Phase 1
NCT04448834	Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL	B-cell Acute Lymphoblastic Leukemia	Drug: Blinatumomab	David Rizzieri, MD Amgen Acrotech Biopharma Duke University	Phase 2
NCT04305145	Infliximab for Treatment of Ipilimumab Colitis	Melanoma Stage III Melanoma Stage IV Side Effect of Drug Colitis	Drug: Infliximab Drug: Methylprednisolone Drug: Prednisone	Massachusetts General Hospital	Phase 2
NCT04227847	A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies	Myelodysplastic Syndrome Acute Myeloid Leukemia	Drug: SEA-CD70	Seattle Genetics, Inc.	Phase 1
NCT04201145	Pembrolizumab + Defactinib In Pleural Mesothelioma	Malignant Pleural Mesothelioma	Drug: Pembrolizumab Drug: Defactinib	Raphael Bueno, MD Merck Sharp & Dohme Corp. Dana-Farber Cancer Institute	Phase 1
NCT04150913	A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity	Non Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non Hodgkin Lymphoma Neurotoxicity Neurotoxicity Syndromes Cytokine Release Syndrome	Drug: Anakinra Drug: Axicabtagene Ciloleucel	Marcela V. Maus, M.D., Ph.D. Kite, A Gilead Company Massachusetts General Hospital	Phase 2
NCT04148352	Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy	Allergies Food Milk	Drug: Dupilumab Other: Placebo	Andrew J Long, PharmD Stanford University	Phase 2
NCT03606746	Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants	Kidney Transplant Rejection	Biological: MDR-103	Medeor Therapeutics, Inc.	Phase 2
NCT04537208	Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older	COVID-19 (Healthy Volunteers)	Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 1 Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 2 Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 1 Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 2 Biological: SARS-CoV-2 vaccine formulation 2 without adjuvant Biological: Placebo (0.9% normal saline)	Sanofi Pasteur, a Sanofi Company GlaxoSmithKline Sanofi	Phase 1  Phase 2
NCT04479241	PVSR1PO and Pembrolizumab in Patients With Recurrent Glioblastoma	Glioblastoma Recurrent Glioblastoma Supratentorial Glioblastoma Brain Tumor	Biological: PVSR1PO Biological: pembrolizumab	Istari Oncology, Inc.	Phase 1
NCT04452214	A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors	Carcinoma, Non-Small-Cell Lung Urothelial Carcinoma Malignant Melanoma Head and Neck Squamous Cell Carcinoma	Drug: CAN04 Drug: Pembrolizumab	Cantargia AB	Phase 1
NCT04426591	Red Blood Cell Survival in Sickle Cell Disease	Sickle Cell Disease	Drug: Biotin Labeled Red Blood Cells	Emory University National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
NCT04394351	Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)	Eosinophilic Esophagitis (EoE)	Drug: Dupilumab Drug: Matching Placebo	Regeneron Pharmaceuticals Sanofi	Phase 3
NCT04098250	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH	Post-Traumatic Headache	Drug: Erenumab Other: Placebo	Mayo Clinic University of Arizona Translational Genomics Research Institute Arizona State University Phoenix VA Health Care System United States Department of Defense Amgen	Phase 2
NCT04383210	Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Locally Advanced Solid Tumor Metastatic Solid Tumor	Drug: Seribantumab	Elevation Oncology	Phase 2
NCT03841565	Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	Recurrent Plasma Cell Myeloma	Biological: Daratumumab Drug: Dexamethasone Drug: Pomalidomide	Academic and Community Cancer Research United National Cancer Institute (NCI) Janssen Scientific Affairs, LLC	Phase 2
NCT04381468	SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Pepinemab Drug: Placebo	Vaccinex Inc. Alzheimer's Drug Discovery Foundation Alzheimer's Association	Phase 1  Phase 2
NCT04471415	First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.	Advanced Solid Tumor Non-Small Cell Lung Cancer Recurrent Squamous Cell Carcinoma of Head and Neck Non Small Cell Lung Cancer Metastatic	Drug: DRP-104 Biological: atezolizumab	Dracen Pharmaceuticals, Inc.	Phase 1  Phase 2
NCT04505722	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants	Healthy	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 3
NCT04501679	A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab Drug: Placebo	Galderma R&D	Phase 3
NCT04501666	An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis	Prurigo Nodularis	Drug: Nemolizumab 30 mg Drug: Placebo	Galderma R&D	Phase 3
NCT04526574	Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥75 Years of Age	Pneumococcal Disease	Biological: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) Other: Saline Biological: Influenza vaccine	Pfizer	Phase 3
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3

## 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT04422210	A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Small Cell Lung Cancer	Drug: Venetoclax Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide	Hoffmann-La Roche	Phase 1
NCT04457284	Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer	Colorectal Adenocarcinoma	Drug: Temozolomide (TMZ) Drug: Cisplatin Drug: Nivolumab	Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb	Phase 2
NCT04432584	A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04416451	Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma	Marginal Zone Lymphoma	Drug: Rituximab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center AbbVie	Phase 2
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04434196	A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Lymphoma, Non-Hodgkin	Drug: CC-99282 Drug: Obinutuzumab	Celgene	Phase 1
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2
NCT04333732	CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAVirus prevenTION	COVID 19	Drug: MR or M-M-R II ® vaccine Drug: Placebo	Washington University School of Medicine COVID -19 Therapeutics Accelerator	Phase 3

### ○ 영국 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04502966	Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction	Allergic Rhinoconjunctivitis Grass Pollen Allergy	Biological: Dupixent® Biological: Grazax® Drug: Dupixent® Placebo Drug: Grazax® Placebo	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) ALK-Abelló A/S Regeneron Pharmaceuticals PPD Rho Federal Systems Division, Inc.	Phase 2
NCT04446000	Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects	Immune Complex-mediated Autoimmune Diseases	Biological: CSL730 Drug: Placebo	CSL Behring	Phase 1
NCT04241601	Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY	Acute Coronary Syndromes	Drug: Interleukin-2 [IL-2] Other: Placebo Dextrose 5% solution	Cambridge University Hospitals NHS Foundation Trust	Phase 2
NCT04432662	Erythropoietin and Darbepoetin in Neonatal Encephalopathy Trial	Neonatal Encephalopathy	Drug: Erythropoietin Drug: Darbepoetin Alfa	Thayyil, Sudhin	Phase 2
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2
NCT04501666	An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis	Prurigo Nodularis	Drug: Nemolizumab 30 mg Drug: Placebo	Galderma R&D	Phase 3
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3
NCT04333732	CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAVirus prevenTION	COVID 19	Drug: MR or M-M-R II ® vaccine Drug: Placebo	Washington University School of Medicine COVID -19 Therapeutics Accelerator	Phase 3

### ○ 프랑스 14건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03949881	Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency	Total Bilateral Limbal Cell Deficiency	Biological: FEMJA transplantation	Hospices Civils de Lyon	Phase 1  Phase 2
NCT04489134	P-glycoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release	Pharmacokinetics	Drug: Treatment A Drug: Treatment B Drug: Treatment C Drug: Treatment D Biological: Pharmacocinetik Genetic: Genetic Other: Selection visit:	Rennes University Hospital	Phase 2
NCT04447898	Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine	Knee Osteoarthritis	Drug: PPV-06 10 µg Drug: PPV-06 50 µg Drug: Placebo	Peptinov SAS	Phase 1
NCT04424056	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease	Covid19	Drug: Anakinra +/- Ruxolitinib (stages 2b/3) Drug: Anakinra and Ruxolitinib (Advanced stage 3) Drug: Tocilizumab +/- ruxolitinib (stages 2b/3) Drug: Tocilizumab and Ruxolitinib (Advanced stage 3) Other: Standard of care	Assistance Publique Hopitaux De Marseille	Phase 3

## 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT04392479	TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracil and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.	Cancer Colorectal Metastasis	Drug: Aflibercept-FOLFIRI Drug: Aflibercept-mFOLFIRI3	GCS IHFB Cognacq-Jay Fondation ARCAD	Phase 3
NCT04356755	Subcutaneous Injections of Autologous ASC to Heal Digital Ulcers in Patients With Scleroderma.	Systemic Sclerosis	Procedure: Adipose tissue harvest Drug: Autologous ASC Drug: Placebo	University Hospital, Toulouse	Phase 2
NCT04013620	CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction	Chronic Kidney Failure	Drug: Belatacept 250 Milligram Intravenous Powder for Solution	Nantes University Hospital	Phase 3
NCT02912897	Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis	Multiple Sclerosis	Biological: Cellular therapy with EBV specific autologous CTL infusion	Nantes University Hospital	Phase 1
NCT04431999	Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage	Trauma Acute Hemorrhage Coagulopathy	Drug: Whole blood transfusion Drug: Fractionated blood products transfusion	Direction Centrale du Service de Santé des Armées TIMC-IMAG Floralis	Phase 3
NCT04108026	Immunotherapy in Patient With Poor General Condition	Non-small Cell Lung Cancer Stage IV	Drug: Durvalumab	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
NCT04501679	A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Prurigo Nodularis	Drug: Nemolizumab Drug: Placebo	Galderma R&D	Phase 3
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04432584	A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3

### ○ 독일 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04537949	A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults	Covid-19 Protection Against COVID-19	Biological: BNT162b3	BioNTech RNA Pharmaceuticals GmbH BioNTech SE	Phase 1  Phase 2
NCT04501666	An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis	Prurigo Nodularis	Drug: Nemolizumab 30 mg Drug: Placebo	Galderma R&D	Phase 3
NCT04432584	A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04471415	First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.	Advanced Solid Tumor Non-Small Cell Lung Cancer Recurrent Squamous Cell Carcinoma of Head and Neck Non Small Cell Lung Cancer Metastatic	Drug: DRP-104 Biological: atezolizumab	Dracen Pharmaceuticals, Inc.	Phase 1  Phase 2

### ○ 중국 24건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04509726	LMP2-Specific IL12-secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Drug: LMBP2-specific TCR-T cell with IL12 auto-secreting element	Xinqiao Hospital of Chongqing TCRCure Biopharma Ltd	Phase 1  Phase 2
NCT04460066	A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.	Esophageal Cancer	Drug: anti-PD-L1 antibody Drug: albumin bound paclitaxel Drug: cisplatin Drug: placebo Procedure: radical resection of esophageal carcinoma	Lee's Pharmaceutical Limited	Phase 1  Phase 2
NCT04458389	A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas	Locally Advanced /Metastatic Solid Tumors Relapsed or Refractory Lymphomas	Drug: TY101	Tayu Huaxia Biotech Medical Group Co., Ltd.	Phase 1  Phase 2
NCT04407741	Phase I/II Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	Solid Tumor Lymphoma	Drug: SHR2554+SHR1701 Drug: SHR1701	Chinese PLA General Hospital	Phase 1  Phase 2
NCT04205435	β-globin Restored Autologous HSC in β-thalassemia Major Patients	β-thalassemia Major	Biological: β-globin restored autologous HSC	Shanghai Bioray Laboratory Inc PLA 923 Hospital	Phase 1  Phase 2
NCT04537442	Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	Drug: IM21 CAR-T cells	Beijing Immunochina Medical Science & Technology Co., Ltd.	Phase 1

# 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT04537156	Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Cervical Intraepithelial Neoplasia Cervical Cancer Condylomata Acuminata	Biological: Nonavalent HPV vaccine Biological: Bivalent HPV vaccine	Xiamen University Xiamen Innovax Biotech Co., Ltd Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	Phase 3
NCT04527068	QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer	Refractory Metastatic Colorectal Cancer pMMR MSS	Drug: Bevacizumab Drug: Tripleitriumab	Second Affiliated Hospital, School of Medicine, Zhejiang University Qilu Pharmaceutical Co., Ltd Shanghai Junshi Bioscience Co., Ltd.	Phase 2
NCT04521205	A Multicenter Clinical Trial: Efficacy, Safety of Fecal Microbiota Transplantation for Inflammatory Bowel Disease	Inflammatory Bowel Disease, Ulcerative Colitis Type	Drug: fecal microbiota capsule	Zhongshan Hospital Xiamen University	Phase 1
NCT04518878	Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)	Immune Thrombocytopenia	Drug: Eltrombopag Drug: rhTPO	Peking University People's Hospital	Phase 1
NCT04517214	Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Drug: Toripalimab Radiation: IMRT to the nasopharynx and neck Drug: Gemcitabine and Cisplatin Chemotherapy Drug: Adjuvant chemotherapy with Capecitabine	Fudan University Fudan University Eye and ENT Hospital Anhui Provincial Hospital Sir Run Run Shaw Hospital Hangzhou Cancer Hospital Ningbo Medical Center Lihuili Hospital The First People's Hospital of Changzhou Cancer Hospital of Chinese Academy of Medical Science, Shenzhen Center Affiliated Cancer Hospital & Institute of Guangzhou Medical University Nanfang Hospital of Southern Medical University Shenzhen People's Hospital First Affiliated Hospital of Xi'anJiaotong University Guangzhou Panyu Central Hospital	Phase 2
NCT04516837	Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)	Immune Thrombocytopenia	Drug: Eltrombopag Drug: rhTPO	Peking University People's Hospital	Phase 2
NCT04516616	Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer	Uterine Cervical Neoplasm Uterine Cervical Cancer Cervical Cancer	Drug: Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)	Huazhong University of Science and Technology Women's Hospital School Of Medicine Zhejiang University Qilu Hospital of Shandong University Obstetrics & Gynecology Hospital of Fudan University First Affiliated Hospital of Chongqing Medical University Army Medical University Peking University People's Hospital Tianjin Medical University General Hospital Harbin Medical University Chongqing University Cancer Hospital	Phase 2
NCT04512417	A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer	Esophageal Cancer	Drug: Camrelizumab+Radiotherapy Drug: Camrelizumab	Zhejiang Cancer Hospital	Phase 2
NCT04511624	Single Dose Tolerability and Pharmacokinetic of IBI112 in Healthy Subjects	Healthy Subjects	Drug: IBI112 dose1 Drug: IBI112 dose2 Drug: IBI112 dose3 Drug: IBI112 dose4 Drug: IBI112 dose5 Drug: IBI112 dose6 Drug: IBI112 dose7	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04508803	Combination of HX008 And Niraparib in GErM-line-mutAtd Metastatic Breast Cancer	Treatment Efficacy	Drug: HX008 , Niraparib Drug: HX008 , Niraparib , Trastuzumab Drug: HX008 , Niraparib , Pyrolitinib	Fudan University	Phase 2
NCT04459663	JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.	Non-small Cell Lung Cancer	Drug: Toripalimab injection combine with Axitinib	Li Zhang, MD Sun Yat-sen University	Phase 2
NCT04262635	Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer	Colorectal Cancer	Drug: Cetuximab, Capecitabine Drug: Cetuximab	Sun Yat-sen University	Phase 3
NCT02226289	Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment	Neoplasm Colorectal Cancer Metastatic Neoplasm	Drug: Bevacizumab	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 2
NCT04498793	Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer	HER2-negative Breast Cancer	Biological: Tislelizumab Drug: Nab paclitaxel Drug: Doxorubicin Drug: Epirubicin Device: Cyclophosphamide	Cancer Institute and Hospital, Chinese Academy of Medical Sciences First Affiliated Hospital Xi'an Jiaotong University Wuhan Union Hospital, China Beijing Huanxing Cancer Hospital	Phase 2
NCT04523272	A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer	Advanced Renal Cancer	Drug: TQB2450 Drug: Anlotinib Drug: Sunitinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
NCT04426825	A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Atezolizumab Drug: Bevacizumab	Hoffmann-La Roche	Phase 2
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3

## 해외 바이오의약품 임상 현황 (2020.08.31~2020.09.06)

한국바이오의약품협회, 2020.9.8.  
출처: ClinicalTrials.gov

NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
-------------	---	-------------------------------------	-----------------------------------	---	---------

### ○ 일본 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04527081	Study of COVID-19 DNA Vaccine (AG0302-COVID19)	COVID-19	Biological: AG0302-COVID19	AnGes, Inc.	Phase 1  Phase 2
NCT04522986	An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection	Severe Acute Respiratory Syndrome Coronavirus 2	Biological: Mesenchymal stem cell	Rohto Pharmaceutical Co., Ltd.	Phase 1
NCT04432584	A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3